[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2887944T3 - Allopregnanolon do leczenia lekoopornego stanu padaczkowego - Google Patents

Allopregnanolon do leczenia lekoopornego stanu padaczkowego

Info

Publication number
PL2887944T3
PL2887944T3 PL13830765T PL13830765T PL2887944T3 PL 2887944 T3 PL2887944 T3 PL 2887944T3 PL 13830765 T PL13830765 T PL 13830765T PL 13830765 T PL13830765 T PL 13830765T PL 2887944 T3 PL2887944 T3 PL 2887944T3
Authority
PL
Poland
Prior art keywords
allopregnanolone
status epilepticus
refractory status
treating refractory
treating
Prior art date
Application number
PL13830765T
Other languages
English (en)
Inventor
Kiran Reddy
Stephen Jay Kanes
Original Assignee
Sage Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics, Inc. filed Critical Sage Therapeutics, Inc.
Publication of PL2887944T3 publication Critical patent/PL2887944T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Fire-Extinguishing Compositions (AREA)
  • Gasification And Melting Of Waste (AREA)
  • Carbon And Carbon Compounds (AREA)
PL13830765T 2012-08-21 2013-08-21 Allopregnanolon do leczenia lekoopornego stanu padaczkowego PL2887944T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261691545P 2012-08-21 2012-08-21
US201361789491P 2013-03-15 2013-03-15
EP13830765.7A EP2887944B1 (en) 2012-08-21 2013-08-21 Allopregnanolone for treating refractory status epilepticus
PCT/US2013/056062 WO2014031792A2 (en) 2012-08-21 2013-08-21 Methods of treating epilepsy or tatus epilepticus

Publications (1)

Publication Number Publication Date
PL2887944T3 true PL2887944T3 (pl) 2022-02-21

Family

ID=50148516

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13830765T PL2887944T3 (pl) 2012-08-21 2013-08-21 Allopregnanolon do leczenia lekoopornego stanu padaczkowego

Country Status (27)

Country Link
US (4) US20140057885A1 (pl)
EP (2) EP3957309A1 (pl)
JP (3) JP6355633B2 (pl)
KR (2) KR102121633B1 (pl)
CN (2) CN111529537A (pl)
AU (4) AU2013305767B2 (pl)
BR (2) BR122021022560B1 (pl)
CA (1) CA2882708A1 (pl)
CY (1) CY1125070T1 (pl)
DK (1) DK2887944T3 (pl)
ES (1) ES2902684T3 (pl)
HK (1) HK1209025A1 (pl)
HR (1) HRP20220005T1 (pl)
HU (1) HUE056838T2 (pl)
IL (5) IL294306B2 (pl)
LT (1) LT2887944T (pl)
MX (1) MX2015002252A (pl)
NZ (1) NZ705410A (pl)
PH (2) PH12015500482A1 (pl)
PL (1) PL2887944T3 (pl)
PT (1) PT2887944T (pl)
RS (1) RS62761B1 (pl)
RU (1) RU2667010C2 (pl)
SG (2) SG11201501911RA (pl)
SI (1) SI2887944T1 (pl)
WO (1) WO2014031792A2 (pl)
ZA (1) ZA201501188B (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP2806877B1 (en) * 2012-01-23 2019-10-09 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
ES2902684T3 (es) 2012-08-21 2022-03-29 Sage Therapeutics Inc Alopregnanolona para el tratamiento del estado epiléptico refractario
EP2925327B1 (en) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
WO2016036724A1 (en) 2014-09-02 2016-03-10 The Texas A&M University System Method of treating organophosphate intoxication
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
SG10202009861SA (en) 2014-10-16 2020-11-27 Sage Therapeutics Inc Compositions and methods for treating cns disorders
EP3224269B1 (en) 2014-11-27 2020-02-26 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10668041B2 (en) 2014-12-08 2020-06-02 Societe Des Produits Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
JP6923440B2 (ja) 2014-12-08 2021-08-18 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 中鎖トリグリセリドを含むてんかんの治療用の組成物及び方法
CN107427458A (zh) * 2015-02-06 2017-12-01 马瑞纳斯制药公司 静脉内加奈索酮制剂及其在治疗癫痫持续状态和其他癫痫发作病症中的用途
US10441580B2 (en) * 2015-02-17 2019-10-15 Vanda Pharmaceuticals, Inc. Iloperidone for the treatment of schizophrenia
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
US10780099B2 (en) 2015-10-16 2020-09-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
SG11201807785VA (en) 2016-03-08 2018-10-30 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
EP4302764A3 (en) 2016-07-11 2024-06-26 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
CA3030420A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019051477A1 (en) * 2017-09-11 2019-03-14 Sage Therapeutics, Inc. METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
US20210228596A1 (en) 2017-10-12 2021-07-29 Sage Therapeutics, Inc. Method of treating cns disorders with neurosteroids and gabaergic compounds
WO2019094724A1 (en) * 2017-11-10 2019-05-16 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
WO2020113099A1 (en) * 2018-11-29 2020-06-04 Gary Aaron Howard Method for treating or preventing seizures associated with an epileptic disorder
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
JP2022543837A (ja) 2019-08-05 2022-10-14 マリナス ファーマシューティカルズ， インコーポレイテッド てんかん重積状態の治療に使用するためのガナキソロン
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
CN113368084A (zh) * 2020-03-10 2021-09-10 上海喀露蓝科技有限公司 含有大麻二酚，丙泊酚前药和别孕烯醇酮前药化合物的药物组合物及其在医药上的应用
JP2023519241A (ja) 2020-03-25 2023-05-10 セージ セラピューティクス， インコーポレイテッド 呼吸器状態の処置のための薬剤の使用
CA3184353A1 (en) * 2020-05-29 2021-12-02 Cerecin Inc. Methods for the treatment of infantile spasms using medium chain triglycerides
CN113925832B (zh) * 2020-07-13 2023-06-16 苏州特瑞药业股份有限公司 一种别孕烯醇酮的脂质体及其制备方法
WO2022109440A1 (en) * 2020-11-23 2022-05-27 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of super refractory status epilepticus
WO2023060020A1 (en) * 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of established status epilepticus

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3117142A (en) 1961-03-01 1964-01-07 Roussel Uclaf Novel preparation of estradiol and estrone
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
US3983111A (en) 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US3865939A (en) 1973-02-23 1975-02-11 Procter & Gamble Edible oils having hypocholesterolemic properties
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
US5847009A (en) 1986-01-14 1998-12-08 Alliance Pharmaceutical Corp. Prophylaxis in the parenteral administration of particulate dispersions in fluorocarbon emulsions
SE8600632D0 (sv) 1986-02-13 1986-02-13 Kabivitrum Ab Novel pharmaceutical composition
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
WO1993005786A1 (en) 1991-09-13 1993-04-01 Cocensys, Inc. Novel gabaa receptor with steroid binding sites
DE69435286D1 (de) 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
NZ282939A (en) 1994-02-14 1998-08-26 Cocensys Inc Androstanes and pregnanes for allosteric modulation of gaba receptors
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
AU3125695A (en) 1994-07-21 1996-02-22 Pharmacia & Upjohn Company Neurologically active aminosteroids
UA48154C2 (uk) 1994-11-23 2002-08-15 Косенсіз Інк. СПОЛУКИ РЯДУ АНДРОСТАНІВ ТА ПРЕГНАНІВ ДЛЯ АЛОСТЕРИЧНОЇ МОДУЛЯЦІЇ РЕЦЕПТОРА <font face="Symbol">g</font>-АМІНОМАСЛЯНОЇ КИСЛОТИ
JP4145350B2 (ja) 1995-06-06 2008-09-03 ユーロ‐セルティック エス． ア． アンドロスタンおよびプレグナン系列の神経活性ステロイド
US6780853B1 (en) * 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
WO1997003677A1 (en) 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
CA2219698C (en) 1996-10-31 2007-09-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US7630757B2 (en) * 1997-01-06 2009-12-08 Flint Hills Scientific Llc System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6316613B1 (en) 1997-07-25 2001-11-13 Beckman Coulter, Inc. Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
CA2321728C (en) 1998-03-11 2008-12-09 Torbjorn Backstrom Epiallopregnanolone in the treatment of cns disorders
US20020198174A1 (en) 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
US6442887B2 (en) 2000-02-25 2002-09-03 Robert L. Sanquist Live bait keeper
IN187686B (pl) 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20020072509A1 (en) 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
CA2443266A1 (en) 2001-02-13 2002-08-22 University Of Florida A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20030032638A1 (en) 2001-05-24 2003-02-13 Kim John J. Delivery of benzodiazepines through an inhalation route
CA2447519C (en) 2001-05-24 2008-09-16 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
JP2003063965A (ja) 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
EP1465942A4 (en) 2002-01-14 2005-06-29 Ansell Healthcare Prod Inc LATEX ARTICLES DETECTABLE THROUGH MAGNETIC
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
EP1539183A4 (en) 2002-08-28 2007-04-25 Hollis Eden Pharmaceuticals THERAPEUTIC TREATMENT METHODS
US9339508B2 (en) 2003-01-17 2016-05-17 Mapreg Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury
US7781421B2 (en) 2003-05-29 2010-08-24 Washington University Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods
WO2005011612A2 (en) * 2003-07-31 2005-02-10 The Research Foundation Of State University Of New York Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ATE497787T1 (de) 2004-03-12 2011-02-15 Cipla Ltd Sterilisationsprozess für steroide
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
ITMI20041763A1 (it) 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
WO2006034196A1 (en) 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
WO2006037016A2 (en) 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
EP1807118B8 (en) 2004-09-29 2014-04-23 Harbor Therapeutics, Inc. Steroid analogs and characterization and treatment methods
BRPI0608087A2 (pt) 2005-02-15 2009-11-10 Elan Pharma Int Ltd formulações injetáveis e em aerossol de benzodiazepina em nanopartìculas
DK2030622T3 (da) 2005-03-24 2011-05-02 Univ Emory Doseringsangivelse af progesteron i behandlingen af en traumatisk hjerneskade
JP2008538748A (ja) * 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
US20110319386A1 (en) 2005-08-26 2011-12-29 Braincells Inc. Neurogenesis by muscarinic receptor modulation
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
US20070287931A1 (en) 2006-02-14 2007-12-13 Dilorenzo Daniel J Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
US20090074677A1 (en) 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
US7813811B2 (en) 2007-02-08 2010-10-12 Neuropace, Inc. Refillable reservoir lead systems
AU2008240259C1 (en) 2007-04-11 2022-11-24 Biomarin Pharmaceutical Inc. Tetrahydrobiopterin compositions and methods of measuring
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2167098B1 (en) 2007-06-11 2018-09-05 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
CA2698172C (en) 2007-06-15 2014-02-18 Cook, Kevin M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
US20100316678A1 (en) 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain
EP2173169B1 (en) * 2007-06-28 2014-05-21 CyDex Pharmaceuticals, Inc. Nasal delivery of aqueous corticosteroid solutions
JP2011507800A (ja) 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト
EP2224927B1 (en) 2008-01-03 2014-08-20 BioMarin Pharmaceutical Inc. Pterin analog for treating bh4 responsive condition
US20090198145A1 (en) 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
US8729070B2 (en) 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
DE102008015366A1 (de) 2008-03-20 2009-09-24 Merck Patent Gmbh Lyophilisierte Nanoemulsion
CZ301216B6 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
WO2010014913A1 (en) * 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
ES2617873T3 (es) * 2008-10-10 2017-06-20 Vm Discovery, Inc. Composiciones y métodos para tratar trastornos de alcoholismo, dolor y otras enfermedades
CN102300566A (zh) * 2008-11-30 2011-12-28 O·扎查尔 血管收缩剂的皮肤应用
WO2010088409A2 (en) * 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US20120142645A1 (en) 2009-03-17 2012-06-07 Marx Christine E Neuroactive steroid compositions and methods of use for lowering cholesterol
WO2011079047A1 (en) 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
KR101747476B1 (ko) * 2010-01-21 2017-06-14 드로브리지 파마슈티컬스 피티와이 엘티디 마취 제제
EP2635333B1 (en) * 2010-11-03 2014-09-03 Sanofi-Aventis Deutschland GmbH Needle cannula containing medicament
US20130309306A1 (en) 2010-12-01 2013-11-21 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
CZ303443B6 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
WO2012116290A2 (en) 2011-02-25 2012-08-30 Washington University Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
FR2973031B1 (fr) 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
US9084797B2 (en) 2011-05-23 2015-07-21 Besins Healthcare Luxembourg Sarl Progesterone treatment for improving sleep quality
KR20130002292A (ko) 2011-06-28 2013-01-07 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
WO2013019711A2 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
PL2753632T3 (pl) 2011-09-08 2023-09-11 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowanie
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
JP2014528485A (ja) 2011-10-14 2014-10-27 セージ セラピューティクス， インコーポレイテッド ３，３−二置換１９−ノルプレグナン化合物およびその使用
EP2785354B1 (en) 2011-11-29 2020-09-09 Amino Up Chemical Co., Ltd. Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function
EP2806877B1 (en) 2012-01-23 2019-10-09 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
WO2013188792A2 (en) 2012-06-15 2013-12-19 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
ES2902684T3 (es) 2012-08-21 2022-03-29 Sage Therapeutics Inc Alopregnanolona para el tratamiento del estado epiléptico refractario
US9765110B2 (en) 2012-10-08 2017-09-19 Washington University Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
US9757391B2 (en) 2012-11-09 2017-09-12 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
EP2925327B1 (en) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
KR101993899B1 (ko) 2012-12-18 2019-09-24 워싱톤 유니버시티 신경활성 19-알콕시-17-치환된 스테로이드, 그의 전구약물, 및 그를 사용한 치료 방법
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
KR102239541B1 (ko) 2013-04-17 2021-04-14 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
CN112110976B (zh) 2013-04-17 2023-08-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
DK3021852T3 (da) 2013-07-19 2021-03-15 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser deraf
US20160229887A1 (en) 2013-08-23 2016-08-11 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20180179247A1 (en) 2014-05-29 2018-06-28 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
SG10202009861SA (en) 2014-10-16 2020-11-27 Sage Therapeutics Inc Compositions and methods for treating cns disorders
ES2808855T3 (es) 2014-10-16 2021-03-02 Sage Therapeutics Inc Composiciones y métodos para tratar trastornos del SNC
EP3224269B1 (en) 2014-11-27 2020-02-26 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
HUE054092T2 (hu) 2015-01-26 2021-08-30 Sage Therapeutics Inc Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások
CN107427458A (zh) 2015-02-06 2017-12-01 马瑞纳斯制药公司 静脉内加奈索酮制剂及其在治疗癫痫持续状态和其他癫痫发作病症中的用途
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2016164763A1 (en) 2015-04-10 2016-10-13 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
GB2541015A (en) 2015-08-06 2017-02-08 Ge Oil & Gas Uk Ltd Subsea flying lead
CN108697712A (zh) 2015-10-14 2018-10-23 加利福尼亚大学董事会 增强β细胞复制和/或存活
US20200306262A1 (en) 2015-11-20 2020-10-01 Sage Therapeutics, Inc. Compounds and methods of their use
SG11201807785VA (en) 2016-03-08 2018-10-30 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
CA3030420A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
EP4302764A3 (en) 2016-07-11 2024-06-26 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US20180050107A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Neurosteroid compositions and methods of use thereof
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
KR20190040043A (ko) 2016-08-23 2019-04-16 세이지 테라퓨틱스, 인크. 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
CA3042213A1 (en) 2016-09-07 2018-03-15 Glia, Llc Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2018169798A1 (en) 2017-03-11 2018-09-20 The Regents Of The University Of California Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers
AU2018255327A1 (en) 2017-04-18 2019-11-07 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US11752115B2 (en) 2017-06-21 2023-09-12 The Board Of Trustees Of The University Of Illinois PPAR-alpha agonist treatment of neuropsychiatric disorders
AU2018290348B2 (en) 2017-06-23 2024-04-04 Ayikoe-Guy MENSAH-NYAGAN Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
CA3104810A1 (en) 2017-06-23 2018-12-27 The Regents Of The University Of California Enhancing gaba's ability to modulate immune responses
AU2018327357B2 (en) 2017-09-07 2024-08-22 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019051477A1 (en) 2017-09-11 2019-03-14 Sage Therapeutics, Inc. METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
TW201919642A (zh) 2017-09-14 2019-06-01 美商賽吉醫療公司 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法
WO2019094724A1 (en) 2017-11-10 2019-05-16 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
BR112020012712A8 (pt) 2017-12-22 2022-03-03 Sage Therapeutics Inc Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc
MA51316A (fr) 2017-12-22 2020-10-28 Sage Therapeutics Inc Compositions et méthodes permettant de traiter les troubles du snc
WO2019140272A1 (en) 2018-01-12 2019-07-18 Sage Therapeutics, Inc. Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
JP2021523938A (ja) 2018-05-04 2021-09-09 アセラス ファーマシュウティカルズ コーポレーション 神経ステロイド誘導体およびその使用
US20210338692A1 (en) 2018-06-12 2021-11-04 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
JP2022504607A (ja) 2018-10-12 2022-01-13 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド
JP7534291B2 (ja) 2018-10-19 2024-08-14 セージ セラピューティクス， インコーポレイテッド ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法
US11311529B2 (en) 2018-11-08 2022-04-26 Varsona Therapeutics, Inc. Topical formulations of 5-α-reductase inhibitors and uses thereof
CA3120856A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics, Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
IL312610A (en) 2018-12-05 2024-07-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
AU2019396139A1 (en) 2018-12-14 2021-07-15 Acerus Biopharma Inc. Active ester derivatives of testosterone, compositions and uses thereof
US20220372067A1 (en) 2018-12-21 2022-11-24 Sage Therapeutics, Inc. 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
WO2020243027A1 (en) 2019-05-24 2020-12-03 Sage Therapeutics, Inc. Compounds, compositions, and methods of use
MA56046A (fr) 2019-05-31 2022-04-06 Sage Therapeutics Inc Stéroïdes neuroactifs et compositions associées
KR20220038681A (ko) 2019-06-27 2022-03-29 세이지 테라퓨틱스, 인크. Cns 장애를 치료하기 위한 조성물 및 방법
WO2020264512A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
AU2020302748A1 (en) 2019-06-27 2022-01-06 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
WO2021113786A1 (en) 2019-12-05 2021-06-10 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
EP4121438A2 (en) 2020-03-18 2023-01-25 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
JP2023519241A (ja) 2020-03-25 2023-05-10 セージ セラピューティクス， インコーポレイテッド 呼吸器状態の処置のための薬剤の使用
AU2021296846A1 (en) 2020-06-24 2022-12-15 Sage Therapeutics, Inc. 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof
EP4181884A1 (en) 2020-07-20 2023-05-24 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
KR20230124916A (ko) 2020-11-25 2023-08-28 세이지 테라퓨틱스, 인크. Cns 장애를 치료하기 위한 조성물 및 방법
CA3206537A1 (en) 2021-01-28 2022-08-04 Sage Therapeutics, Inc. Use of neuroactive steroids for treatment of sexual dysfunction
US20240148756A1 (en) 2021-02-18 2024-05-09 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
IL305858A (en) 2021-03-17 2023-11-01 Sage Therapeutics Inc Steroid C21-N-pyrazolyl 19-NOR C3,3-dimuter for the treatment of major depressive disorder
US20240238314A1 (en) 2021-04-12 2024-07-18 Sage Therapeutics, Inc. Treatment of essential tremor
AU2022267304A1 (en) 2021-04-29 2023-11-02 Sage Therapeutics, Inc. Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female
CA3218072A1 (en) 2021-04-29 2022-11-03 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
KR20240148425A (ko) 2022-02-16 2024-10-11 세이지 테라퓨틱스, 인크. Cns-관련 장애의 치료를 위한 신경활성 스테로이드
TW202341996A (zh) 2022-02-28 2023-11-01 美商賽吉醫療公司 用於治療腸胃疾病或病狀之神經活性類固醇

Also Published As

Publication number Publication date
IL275725A (en) 2020-08-31
IL237352A0 (en) 2015-04-30
PH12020500065A1 (en) 2021-04-26
NZ705410A (en) 2018-03-23
JP2018154652A (ja) 2018-10-04
RU2018132041A3 (pl) 2022-03-31
CN111529537A (zh) 2020-08-14
WO2014031792A3 (en) 2014-04-10
IL304912A (en) 2023-10-01
RS62761B1 (sr) 2022-01-31
US20190269699A1 (en) 2019-09-05
CY1125070T1 (el) 2023-06-09
JP6829224B2 (ja) 2021-02-10
MX2015002252A (es) 2015-07-21
IL264414A (en) 2019-02-28
HK1209025A1 (en) 2016-03-24
AU2013305767A1 (en) 2015-03-19
IL264414B (en) 2020-07-30
ES2902684T3 (es) 2022-03-29
WO2014031792A2 (en) 2014-02-27
PT2887944T (pt) 2022-01-10
RU2667010C2 (ru) 2018-09-13
JP6355633B2 (ja) 2018-07-11
IL294306B2 (en) 2024-01-01
RU2015109956A (ru) 2016-10-20
US20140057885A1 (en) 2014-02-27
IL294306B1 (en) 2023-09-01
AU2018220028B2 (en) 2020-04-02
AU2020204359A1 (en) 2020-07-23
BR122021022560B1 (pt) 2022-08-09
EP3957309A1 (en) 2022-02-23
US20190038639A1 (en) 2019-02-07
KR102305359B1 (ko) 2021-09-24
CA2882708A1 (en) 2014-02-27
AU2013305767B2 (en) 2018-05-24
SI2887944T1 (sl) 2022-02-28
CN104736159A (zh) 2015-06-24
JP2015527371A (ja) 2015-09-17
AU2018220028A1 (en) 2018-09-06
EP2887944A4 (en) 2016-02-10
KR20150054846A (ko) 2015-05-20
DK2887944T3 (da) 2022-01-03
EP2887944A2 (en) 2015-07-01
SG10201608148TA (en) 2016-11-29
RU2018132041A (ru) 2018-11-13
US20220152050A1 (en) 2022-05-19
BR112015003747A2 (pt) 2017-07-04
KR20200067922A (ko) 2020-06-12
HRP20220005T1 (hr) 2022-04-01
EP2887944B1 (en) 2021-10-06
SG11201501911RA (en) 2015-04-29
AU2022202277A1 (en) 2022-04-21
HUE056838T2 (hu) 2022-04-28
US12048706B2 (en) 2024-07-30
KR102121633B1 (ko) 2020-06-10
IL237352B (en) 2019-05-30
PH12015500482A1 (en) 2015-04-20
JP2021059608A (ja) 2021-04-15
IL294306A (en) 2022-08-01
ZA201501188B (en) 2016-09-28
LT2887944T (lt) 2022-01-10
IL275725B (en) 2022-08-01

Similar Documents

Publication Publication Date Title
LT2887944T (lt) Alopregnanolonas, skirtas atsparios epileptinės būklės gydymui
HUE046163T2 (hu) Tûzálló tárgy
HUE055268T2 (hu) Tûzálló tárgy
ZA201906339B (en) Methods for treating pruritus
HK1215170A1 (zh) 治療精神分裂症的方法和組合物
ZA201500697B (en) Residue hydrocracking
IL253421B (en) Compounds for the treatment of fibrosis (Leifat)
EP2830648A4 (en) METHODS OF TREATING NEOPLASIA
EP2771505A4 (en) LAUNDRY TREATMENT APPARATUS
EP2693144A4 (en) ROOF FOR ELECTRIC OVEN
PT2722143T (pt) Processo para fabrico de uma folha inorgânica
PL2621910T3 (pl) Ulepszona kontrola procesu EO
EP2815016A4 (en) LAUNDRY TREATMENT APPARATUS
EP2871247A4 (en) METHOD FOR OPERATING A HIGH FOOD
PL2940386T3 (pl) Piec do topienia odpadów
EP2916767A4 (en) DEVICES FOR TREATING TEETH NECKS
ZA201503005B (en) Ingenol-derived compounds useful for treating cancer
SI2872455T1 (sl) Aparat za oblikovanje mineralnih vlaken
PL2809760T3 (pl) Sposób zmniejszania przykrych zapachów
EP2824095A4 (en) SHAPED FIRESIDE PRODUCT AND METHOD FOR THE PRODUCTION THEREOF
EP3040426A4 (en) METHOD OF OPERATING A HIGH STOVE
EP2908813A4 (en) COMPOUNDS FOR TREATING RAC-GTPASE MEDIA DISORDER
EP2811038A4 (en) PROCESS FOR SLAG REDUCTION
EP2840152A4 (en) OPERATING METHOD FOR A COMBUSTION OVEN WITH FERROCOKE
HK1209040A1 (en) Methods for treating vestibulotoxicity